Meningococcal Vaccines: Current Status and Emerging Strategies
Related Experiment Video
Updated: Feb 13, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Pumtiwitt C McCarthy1, Abeer Sharyan2, Laleh Sheikhi Moghaddam3
1Department of Chemistry, Morgan State University, Baltimore, MD 21251, USA. Pumtiwitt.McCarthy@morgan.edu.
Abstract:
Neisseria meningitidis causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world. There are a number of vaccines (polysaccharide-based, glycoconjugate, protein-based and combined conjugate vaccines) that are approved to target five of the six disease-causing serogroups of the pathogen. Immunization strategies have been effective at helping to decrease the global incidence of meningococcal meningitis. Researchers continue to enhance these efforts through discovery of new antigen targets that may lead to a broadly protective vaccine and development of new methods of homogenous vaccine production. This review describes current meningococcal vaccines and discusses some recent research discoveries that may transform vaccine development against N. meningitidis in the future.
Related Concept Videos
Vaccinations
Emerging Adulthood
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Introduction Cardiac Emergencies
Marcia's Theory of Identity Status
Electrical Current

